Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

To assess long-term drug survival and effectiveness in biological drug-naïve patients with rheumatoid arthritis (RA), starting infliximab as first treatment, in the period 2000-2009, comparing different calendar years.
Lingua originaleEnglish
pagine (da-a)524-530
Numero di pagine7
RivistaClinical and Experimental Rheumatology
Volume33
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthralgia
  • Arthritis, Rheumatoid
  • C-Reactive Protein
  • Demography
  • Disability Evaluation
  • Female
  • Humans
  • Infliximab
  • Italy
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Pain Measurement
  • Patient Acuity
  • Patient Outcome Assessment
  • Registries
  • Remission Induction
  • Rheumatoid Factor
  • Time-to-Treatment

Fingerprint

Entra nei temi di ricerca di 'Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years'. Insieme formano una fingerprint unica.

Cita questo